Harmful viruses continue to evolve, and Apriori Bio’s goal is to provide humanity with variant-proof protection against these viruses. To achieve that goal, Apriori is building a platform, called Octavia, to design vaccines and antibody drugs that combat existing and potential viral variants. The Octavia platform applies protein display, mutational scanning, single-cell sorting, and deep sequencing to create maps of potential viral variants based on their ability to bind human cells and evade antibodies. Apriori analyzes these maps to identify protective antibody combinations and inform development of new vaccines and antibody drugs. Apriori envisions a future where our vaccines and antibody drugs protect us from not only an existing virus but its future variants that are likely to emerge.
Claim company profile to post jobs directly on this page and this website.